Skinvisible, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 19, 2021 at 04:41 pm
Share
Skinvisible, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 0.203352 million compared to USD 0.409759 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.04 compared to USD 0.09 a year ago.
For the nine months, net loss was USD 0.907371 million compared to USD 1.15 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.26 a year ago. Diluted loss per share from continuing operations was USD 0.2 compared to USD 0.26 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare, and formulating over forty topical skin products. Its flagship product, Pivotal, is a patented polymer delivery system technology, Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. It is also exploring opportunities in medical markets outside the dermatology market.